Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-Related Gene Variants as Modifiers of Multiple Sclerosis Severity.

International journal of molecular sciences·2026
Same author

Glatiramer Acetate Therapy Induces DNA Methylation Changes in Immune Cells of Multiple Sclerosis Patients: A Pilot Study.

International journal of molecular sciences·2026
Same author

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.

Journal of the neurological sciences·2026
Same author

The role of 5-HT<sub>2B</sub>-serotonin receptor in the modulatory effect of fluoxetine on interaction of macrophages with CD4<sup>+</sup> T-cells in multiple sclerosis.

International immunopharmacology·2025
Same author

[Effect of urolithin A on production of interleukins 6 and 10 by immune cells from patients with MS and healthy donors].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025

Related Experiment Video

Updated: May 28, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Anti-Inflammatory Properties of Curcumin as Add-On Therapy in Patients with MS-Prospective, Comparative, Randomized,

Anna Kukushkina1,2, Vladimir Rogovskii1,3, Olga Zhilenkova4

  • 1Department of Neuroimmunology, Institute of Clinical Neurology, Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency, 117513 Moscow, Russia.

Pharmaceutics
|May 27, 2026
PubMed
Summary

Micellar curcumin add-on therapy improved outcomes for multiple sclerosis (MS) patients with suboptimal response to interferon-beta (IFN-β). This treatment reduced relapses and enhanced clinical benefits, suggesting a promising therapeutic strategy for MS management.

Keywords:
add-on therapycurcumingut microbiotamicrobiota markersmultiple sclerosisneuroinflammation

More Related Videos

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Related Experiment Videos

Last Updated: May 28, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Area of Science:

  • Neuroimmunology
  • Pharmacology
  • Microbiomics

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability, managed by disease-modifying therapies (DMTs).
  • Low-efficacy DMTs like interferon-beta (IFN-β) can be insufficient, necessitating exploration of add-on therapies.
  • Curcumin, a natural polyphenol with immunomodulatory properties, offers a potential therapeutic agent, especially in bioavailable micellar forms.

Purpose of the Study:

  • To investigate the efficacy of micellar curcumin as an add-on therapy to IFN-β in MS patients with suboptimal response.
  • To evaluate the impact of micellar curcumin on clinical and laboratory parameters in this patient cohort.

Main Methods:

  • A randomized controlled trial involving 60 MS patients with suboptimal IFN-β response.
  • Patients were assigned to receive either IFN-β plus micellar curcumin or IFN-β alone for 6 months, followed by a 6-month follow-up.
  • Clinical outcomes, neurological disability scores (EDSS), depression, inflammatory markers (IFN-γ, IL-6), MRI activity, and microbiota markers were assessed.

Main Results:

  • Add-on micellar curcumin significantly increased the proportion of relapse-free patients (90% vs. 57%) and reduced exacerbation risk (HR=0.2).
  • Treatment stabilized EDSS scores, improved depression symptoms (p=0.05), and decreased plasma IFN-γ levels (p=0.02).
  • Trends towards reduced MRI lesion activity and specific microbial markers (i16a) were observed, alongside in vitro inhibition of IL-6 production by curcumin.

Conclusions:

  • Micellar curcumin as an add-on therapy can enhance IFN-β efficacy in MS patients.
  • This approach improves clinical outcomes and modulates inflammatory and microbial profiles.
  • Micellar curcumin represents a potentially valuable strategy for managing MS patients with suboptimal responses to standard therapies.